Volume 95 Issue 5 | p. 13 | Concentrates
Issue Date: January 30, 2017

Immunotherapy-focused Cue Biopharma launches

Department: Business
Keywords: drug development, start-ups, biotech, Cue Biopharma, cancer immunotherapy

Cue Biopharma has emerged from stealth with $26 million in funding to develop T-cell receptor-targeted biologics. Founded in 2015 with $10 million in seed funding, Cue hopes to tackle cancer and autoimmune diseases by developing biologics that will modulate the activity of specific sets of T cells. By outfitting an antibody with both an engineered T-cell signaling ligand and a peptide complex specific for disease-relevant T cells, Cue can elicit a highly specific response, either stimulating T cells to combat cancer or dampening the T-cell response in autoimmune diseases. The biotech firm has two drug candidates in preclinical studies for cancer.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment